Clinical Trial Update: Open-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects With Mild To Moderate Alzheimer's Disease [Phase 2]

View source ↗

Summary

An open-label extension trial assessed the long-term safety of rosiglitazone in mild-to-moderate Alzheimer's disease; the Phase 2 study has completed and result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Rosiglitazone (rosiglitazone)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED | Results posted: 2017-05-23